Fecal DNA Testing in Screening for Colorectal Cancer in Average-Risk Adults. Executive Summary. Effective Health Care Program. Comparative Effectiveness Review Number 52.

摘要

Colorectal cancer (CRC) is the third most common cancer in both men and women and is the third leading cause of cancer deaths in the United States. Incidence and mortality rates for CRC have declined over the past two decades, corresponding with an increase in self-reported screening rates. However, screening rates remain suboptimal. While different U.S. guideline-issuing organizations agree on the majority of recommended CRC screening options, there are differences between some recommended options, such as fecal DNA testing. In 2008, the United States Preventive Services Task Force (USPSTF) found that evidence was insufficient to recommend fecal DNA testing for CRC screening. However, the American Cancer Society (ACS), the U.S. Multi-Society Task Force (MSTF) on Colorectal Cancer, and the American College of Radiology (ACR) collectively recommended fecal DNA testing as an alternative screening method. The ACS-MSTF-ACR's recommendation was based on a lower threshold of evidence than that of the USPSTF.